Ally Financial Inc. Invests $1.72 Million in Zimmer Biomet Holdings, Inc. $ZBH

Ally Financial Inc. acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 20,000 shares of the medical equipment provider's stock, valued at approximately $1,722,000.

Other large investors have also recently added to or reduced their stakes in the company. DV Equities LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at $25,000. Tacita Capital Inc acquired a new stake in shares of Zimmer Biomet in the second quarter valued at $26,000. Monetary Solutions Ltd acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $30,000. Gen Wealth Partners Inc bought a new position in Zimmer Biomet during the fourth quarter valued at about $31,000. Finally, Elevation Wealth Partners LLC boosted its stake in Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 229 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Zacks Research downgraded shares of Zimmer Biomet from a "hold" rating to a "strong sell" rating in a report on Monday, July 27th. Sanford C. Bernstein lifted their price objective on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a research note on Thursday, August 6th. Canaccord Genuity Group boosted their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a report on Monday, August 10th. Royal Bank Of Canada increased their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, August 6th. Finally, Wells Fargo & Company reduced their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an "equal weight" rating for the company in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet currently has an average rating of "Hold" and an average price target of $104.42.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.28% of the company's stock.

Zimmer Biomet Trading Up 0.0%

Shares of NYSE:ZBH opened at $101.01 on Monday. The firm has a fifty day moving average of $92.64 and a two-hundred day moving average of $91.04. The firm has a market capitalization of $19.27 billion, a P/E ratio of 24.58, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.Zimmer Biomet's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the company earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source